Peter Van Vlasselaer

Peter is a Venture Partner based in our San Francisco office, focused on working with emerging clinical biotechnology companies. He has over 25 years of experience in the biotech industry, including Executive Chairman roles at SR One portfolio companies True North Therapeutics (acquired by Bioverativ, now part of Sanofi) and iPierian (acquired by BMS). Most recently, Peter was the Founder, President, and CEO of ARMO BioSciences (ARMO), a company he led through to its acquisition by Eli Lilly in 2018 for $1.6 billion, shortly after its IPO. Prior to that, Peter founded and held CEO positions at Arresto Biosciences (acquired by Gilead) and Avidia (acquired by AMGEN). Prior to that, he held Executive positions at InterMune (ITMN) and Dendreon (DNDN). He currently serves on the Boards of Amphivena, where he is Executive Chair, Asceneuron where he is Chair, and RGENIX.